Skip to main content
Top
Published in: Tumor Biology 5/2015

01-05-2015 | Research Article

Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma

Authors: Ning Lu, Tao Lin, Lin Wang, Mei Qi, Zhiyan Liu, Hongyan Dong, Xiying Zhang, Chunyan Zhai, Yan Wang, Long Liu, Lei Xiang, Lei Qi, Bo Han, Jinsong Li

Published in: Tumor Biology | Issue 5/2015

Login to get access

Abstract

The sex-determining region Y-box 4 (SOX4), a transcription factor, is involved in various developmental processes. It has been reported in multiple human cancers. However, the prognostic value and its exact role in chondrosarcoma remain poorly understood. In the current study, SOX4 was overexpressed in 28 of 92 (30.4 %) interpretable chondrosarcoma patients compared with 3 of 43 (6.9 %) interpretable chondroma cases (P = 0.003). Its overexpression in chondrosarcoma was significantly associated with histological grade (P < 0.001) and the presence of tumor recurrence (P = 0.041). In addition, SOX4 overexpression was notably correlated with c-MYC (P = 0.011) and P53 (P = 0.029) expression as well as high Ki67 labeling index (LI) (P < 0.001) in our cohort. More importantly, we found that SOX4 was an unfavorable independent prognostic factor for chondrosarcoma patients with low histological grade. Functionally, SOX4 silencing significantly suppressed the proliferation, migratory, and invasive capacity of SW1353 cells, suggesting an oncogenic role of SOX4 in chondrosarcoma in vitro. In an attempt of characterizing SOX4 overexpression mechanism, we identified miR-30a as a tumor suppressor that directly targets SOX4 in chondrosarcoma cells. Clinically, miR-30a expression was negatively correlated with SOX4 expression in chondrosarcoma cases. In all, we identified that SOX4 was oncogenic in chondrosarcoma and negatively regulated by miR-30a in vitro. Importantly, SOX4 overexpression may serve as a prognostic marker for patients with low-histological-grade chondrosarcoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bovee JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer. 2010;10:481–8.CrossRefPubMed Bovee JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer. 2010;10:481–8.CrossRefPubMed
2.
go back to reference van Oosterwijk JG, Anninga JK, Gelderblom H, Cleton-Jansen AM, Bovee JV. Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol Oncol Clin North Am. 2013;27:1021–48.CrossRefPubMed van Oosterwijk JG, Anninga JK, Gelderblom H, Cleton-Jansen AM, Bovee JV. Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol Oncol Clin North Am. 2013;27:1021–48.CrossRefPubMed
3.
go back to reference Kamachi Y, Kondoh H. Sox proteins: regulators of cell fate specification and differentiation. Development. 2013;140:4129–44.CrossRefPubMed Kamachi Y, Kondoh H. Sox proteins: regulators of cell fate specification and differentiation. Development. 2013;140:4129–44.CrossRefPubMed
4.
go back to reference Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16:2813–28.CrossRefPubMedPubMedCentral Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16:2813–28.CrossRefPubMedPubMedCentral
5.
go back to reference Sekiya I, Vuoristo JT, Larson BL, Prockop DJ. In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. Proc Natl Acad Sci U S A. 2002;99:4397–402.CrossRefPubMedPubMedCentral Sekiya I, Vuoristo JT, Larson BL, Prockop DJ. In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. Proc Natl Acad Sci U S A. 2002;99:4397–402.CrossRefPubMedPubMedCentral
6.
go back to reference Reppe S, Rian E, Jemtland R, Olstad OK, Gautvik VT, Gautvik KM. Sox-4 messenger RNA is expressed in the embryonic growth plate and regulated via the parathyroid hormone/parathyroid hormone-related protein receptor in osteoblast-like cells. J Bone Miner Res. 2000;15:2402–12.CrossRefPubMed Reppe S, Rian E, Jemtland R, Olstad OK, Gautvik VT, Gautvik KM. Sox-4 messenger RNA is expressed in the embryonic growth plate and regulated via the parathyroid hormone/parathyroid hormone-related protein receptor in osteoblast-like cells. J Bone Miner Res. 2000;15:2402–12.CrossRefPubMed
7.
go back to reference Jafarnejad SM, Ardekani GS, Ghaffari M, Li G. Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. Cell Mol Life Sci. 2013;70:2677–96.CrossRefPubMed Jafarnejad SM, Ardekani GS, Ghaffari M, Li G. Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. Cell Mol Life Sci. 2013;70:2677–96.CrossRefPubMed
8.
go back to reference Liao YL, Sun YM, Chau GY, Chau YP, Lai TC, Wang JL, et al. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene. 2008;27:5578–89.CrossRefPubMed Liao YL, Sun YM, Chau GY, Chau YP, Lai TC, Wang JL, et al. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene. 2008;27:5578–89.CrossRefPubMed
9.
go back to reference Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res. 2006;66:3434–42.CrossRefPubMed Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res. 2006;66:3434–42.CrossRefPubMed
10.
go back to reference Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, et al. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial–mesenchymal transition in vitro. Prostate Cancer Prostatic Dis. 2013;16:301–7.CrossRefPubMed Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, et al. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial–mesenchymal transition in vitro. Prostate Cancer Prostatic Dis. 2013;16:301–7.CrossRefPubMed
11.
go back to reference Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res. 2009;69:709–17.CrossRefPubMedPubMedCentral Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res. 2009;69:709–17.CrossRefPubMedPubMedCentral
12.
go back to reference Reymann S, Borlak J. Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network. BMC Syst Biol. 2008;2:46.CrossRefPubMedPubMedCentral Reymann S, Borlak J. Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network. BMC Syst Biol. 2008;2:46.CrossRefPubMedPubMedCentral
13.
go back to reference Morrison C, Radmacher M, Mohammed N, Suster D, Auer H, Jones S, et al. MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol. 2005;23:9369–76.CrossRefPubMed Morrison C, Radmacher M, Mohammed N, Suster D, Auer H, Jones S, et al. MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol. 2005;23:9369–76.CrossRefPubMed
14.
go back to reference Si X, Liu Z. Expression and significance of cell cycle-related proteins cyclin Dl, CDK4, p27, E2F-l and Ets-1 in chondrosarcoma of the jaws. Oral Oncol. 2001;37:431–6.CrossRefPubMed Si X, Liu Z. Expression and significance of cell cycle-related proteins cyclin Dl, CDK4, p27, E2F-l and Ets-1 in chondrosarcoma of the jaws. Oral Oncol. 2001;37:431–6.CrossRefPubMed
15.
go back to reference Kolupaeva V, Basilico C. Overexpression of cyclin E/CDK2 complexes overcomes FGF-induced cell cycle arrest in the presence of hypophosphorylated Rb proteins. Cell Cycle. 2012;11:2557–66.CrossRefPubMedPubMedCentral Kolupaeva V, Basilico C. Overexpression of cyclin E/CDK2 complexes overcomes FGF-induced cell cycle arrest in the presence of hypophosphorylated Rb proteins. Cell Cycle. 2012;11:2557–66.CrossRefPubMedPubMedCentral
17.
go back to reference Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475–88.CrossRefPubMed Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475–88.CrossRefPubMed
18.
go back to reference Tsukamoto O, Miura K, Mishima H, Abe S, Kaneuchi M, Higashijima A, et al. Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol. 2014;132:715–21.CrossRefPubMed Tsukamoto O, Miura K, Mishima H, Abe S, Kaneuchi M, Higashijima A, et al. Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol. 2014;132:715–21.CrossRefPubMed
19.
go back to reference Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog. 2013 Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog. 2013
21.
go back to reference Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69:4851–60.CrossRefPubMed Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69:4851–60.CrossRefPubMed
22.
go back to reference Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–52.CrossRefPubMedPubMedCentral Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–52.CrossRefPubMedPubMedCentral
23.
go back to reference Liu S, Patel SH, Ginestier C, Ibarra I, Martin-Trevino R, Bai S, et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet. 2012;8:e1002751.CrossRefPubMedPubMedCentral Liu S, Patel SH, Ginestier C, Ibarra I, Martin-Trevino R, Bai S, et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet. 2012;8:e1002751.CrossRefPubMedPubMedCentral
24.
go back to reference Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083–93.CrossRefPubMedPubMedCentral Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083–93.CrossRefPubMedPubMedCentral
25.
go back to reference Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, et al. Metformin inhibits epithelial–mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun. 2014;452:746–52.CrossRefPubMed Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, et al. Metformin inhibits epithelial–mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun. 2014;452:746–52.CrossRefPubMed
26.
go back to reference Wang C, Wang L, Su B, Lu N, Song J, Yang X, et al. Serine protease inhibitor Kazal type 1 promotes epithelial–mesenchymal transition through EGFR signaling pathway in prostate cancer. Prostate. 2014;74:689–701.CrossRefPubMed Wang C, Wang L, Su B, Lu N, Song J, Yang X, et al. Serine protease inhibitor Kazal type 1 promotes epithelial–mesenchymal transition through EGFR signaling pathway in prostate cancer. Prostate. 2014;74:689–701.CrossRefPubMed
27.
go back to reference Nawa G, Ueda T, Mori S, Yoshikawa H, Fukuda H, Ishiguro S, et al. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer. 1996;69:86–91.CrossRefPubMed Nawa G, Ueda T, Mori S, Yoshikawa H, Fukuda H, Ishiguro S, et al. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer. 1996;69:86–91.CrossRefPubMed
28.
go back to reference Boeuf S, Kunz P, Hennig T, Lehner B, Hogendoorn P, Bovee J, et al. A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. J Pathol. 2008;216:158–66.CrossRefPubMed Boeuf S, Kunz P, Hennig T, Lehner B, Hogendoorn P, Bovee J, et al. A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. J Pathol. 2008;216:158–66.CrossRefPubMed
29.
go back to reference Pan X, Zhao J, Zhang WN, Li HY, Mu R, Zhou T, et al. Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc Natl Acad Sci U S A. 2009;106:3788–93.CrossRefPubMedPubMedCentral Pan X, Zhao J, Zhang WN, Li HY, Mu R, Zhou T, et al. Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc Natl Acad Sci U S A. 2009;106:3788–93.CrossRefPubMedPubMedCentral
30.
go back to reference Hur W, Rhim H, Jung CK, Kim JD, Bae SH, Jang JW, et al. SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro. Carcinogenesis. 2010;31:1298–307.CrossRefPubMed Hur W, Rhim H, Jung CK, Kim JD, Bae SH, Jang JW, et al. SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro. Carcinogenesis. 2010;31:1298–307.CrossRefPubMed
31.
go back to reference Eguchi T, Watanabe K, Hara ES, Ono M, Kuboki T, Calderwood SK. OstemiR: a novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation from mesencymal stem cells. PLoS One. 2013;8:e58796.CrossRefPubMedPubMedCentral Eguchi T, Watanabe K, Hara ES, Ono M, Kuboki T, Calderwood SK. OstemiR: a novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation from mesencymal stem cells. PLoS One. 2013;8:e58796.CrossRefPubMedPubMedCentral
Metadata
Title
Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma
Authors
Ning Lu
Tao Lin
Lin Wang
Mei Qi
Zhiyan Liu
Hongyan Dong
Xiying Zhang
Chunyan Zhai
Yan Wang
Long Liu
Lei Xiang
Lei Qi
Bo Han
Jinsong Li
Publication date
01-05-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-3026-2

Other articles of this Issue 5/2015

Tumor Biology 5/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine